Gene therapy progress and prospects - Vectorology: Design and production of expression cassettes in AAV vectors

Gene Therapy

Volumn 13, Issue 10, 2006, Pages 805-813

  Le Bec, C ^a   Douar, A M ^a  

^a GÉNÉTHON   (France)

Author keywords

Gene regulation; Gene targeting; scAAV; Trans splicing

Indexed keywords

COMPLEMENTARY DNA; DOXYCYCLINE; LENTIVIRUS VECTOR; MESSENGER RNA; PARVOVIRUS VECTOR; RAPAMYCIN; RETROVIRUS VECTOR; SMALL INTERFERING RNA; TETRACYCLINE; TRANSMEMBRANE CONDUCTANCE REGULATOR;

CLINICAL TRIAL; CYSTIC FIBROSIS; DNA MODIFICATION; DUCHENNE MUSCULAR DYSTROPHY; ENCEPHALOMYOCARDITIS VIRUS; ENHANCER REGION; GENE CASSETTE; GENE CONTROL; GENE CONVERSION; GENE EXPRESSION; GENE INSERTION; GENE SEQUENCE; GENE TARGETING; GENE THERAPY; GENE TRANSFER; GENETIC ENGINEERING; GENETIC ENHANCEMENT; GENOME ANALYSIS; HEMOPHILIA A; HEPATITIS VIRUS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFECTION; INSULIN DEPENDENT DIABETES MELLITUS; INTERNAL RIBOSOME ENTRY SITE; INVERTED TERMINAL REPEAT; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; SAFETY; SEQUENCE ANALYSIS; SEROTYPE; TRANS SPLICING; VIRAL GENE DELIVERY SYSTEM; VIRUS CAPSID; VIRUS GENOME;

ADENO-ASSOCIATED VIRUS; ENCEPHALOMYOCARDITIS VIRUS; LENTIVIRUS; MIRIDAE; PARVOVIRUS;

EID: 33646370763     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/sj.gt.3302724     Document Type: Review

References (62)

1. Flotte TR. Gene therapy progress and prospects: Recombinant adeno-associated virus (rAAV) vectors. Gene Therapy 2004; 11: 805-810.
2. Gao G, Vandenberghe LH, Alvira MR, Lu Y, Calcedo R, Zhou X et al. Clades of Adeno-associated viruses are widely disseminated in human tissues. J Virol 2004; 78: 6381-6388.
3. Choi VW, McCarty DM, Samulski RJ. AAV hybrid serotypes: Improved vectors for gene delivery. Curr Gene Ther 2005; 5: 299-310.
4. Grimm D, Kay MA. From virus evolution to vector revolution: Use of naturally occurring serotypes of adeno-associated virus (AAV) as novel vectors for human gene therapy. Curr Gene Ther 2003; 3: 281-304.
5. Ostedgaard LS, Rokhlina T, Karp PH, Lashmit P, Afione S, Schmidt M et al. A shortened adeno-associated virus expression cassette for CFTR gene transfer to cystic fibrosis airway epithelia. Proc Natl Acad Sci USA 2005; 102: 2952-2957.
6. Everett RS, Evans HK, Hodges BL, Ding EY, Serra DM, Amalfitano A. Strain-specific rate of shutdown of CMV enhancer activity in murine liver confirmed by use of persistent [E1(-), E2b(-)] adenoviral vectors. Virology 2004; 325: 96-105.
7. Park J, Murray GJ, Limaye A, Quirk JM, Gelderman MP, Brady RO et al. Long-term correction of globotriaosylceramide storage in Fabry mice by recombinant adeno-associated virus-mediated gene transfer. Proc Natl Acad Sci USA 2003; 100: 3450-3454.
8. Sirninger J, Muller C, Braag S, Tang Q, Yue H, Detrisac C et al. Functional characterization of a recombinant adeno-associated virus 5-pseudotyped cystic fibrosis transmembrane conductance regulator vector. Hum Gene Ther 2004; 15: 832-841.
9. Shevtsova Z, Malik JM, Michel U, Bahr M, Kugler S. Promoters and serotypes: Targeting of adeno-associated virus vectors for gene transfer in the rat central nervous system in vitro and in vivo. Exp Physiol 2005; 90: 53-59.
10. Liu YL, Mingozzi F, Rodriguez-Colon SM, Joseph S, Dobrzynski E, Suzuki T et al. Therapeutic levels of factor IX expression using a muscle-specific promoter and adeno-associated virus serotype 1 vector. Hum Gene Ther 2004; 15: 783-792.
11. Yoshimura M, Sakamoto M, Ikemoto M, Mochizuki Y, Yuasa K, Miyagoe-Suzuki Y et al. AAV vector-mediated microdystrophin expression in a relatively small percentage of mdx myofibers improved the mdx phenotype. Mol Ther 2004; 10: 821-828.
12. Zhang G, Ludtke JJ, Thioudellet C, Kleinpeter P, Antoniou M, Herweijer H et al. Intraarterial delivery of naked plasmid DNA expressing full-length mouse dystrophin in the mdx mouse model of duchenne muscular dystrophy. Hum Gene Ther 2004; 15: 770-782.
13. Zhong S, Sun S, Teng BB. The recombinant adeno-associated virus vector (rAAV2)-mediated apolipoprotein B mRNA-specific hammerhead ribozyme: A self-complementary AAV2 vector improves the gene expression. Genet Vaccines Ther 2004; 2: 5.
14. Toniatti C, Bujard H, Cortese R, Ciliberto G. Gene therapy progress and prospects: Transcription regulatory systems. Gene Therapy 2004; 11: 649-657.
15. Goverdhana S, Puntel M, Xiong W, Zirger JM, Barcia C, Curtin JF et al. Regulatable gene expression systems for gene therapy applications: progress and future challenges. Mol Ther 2005; 12: 189-211.
16. Jiang L, Rampalli S, George D, Press C, Bremer EG, O'Gorman MR et al. Tight regulation from a single tet-off rAAV vector as demonstrated by flow cytometry and quantitative, real-time PCR. Gene Therapy 2004; 11: 1057-1067.
17. Chenuaud P, Larcher T, Rabinowitz JE, Provost N, Joussemet B, Bujard H et al. Optimal design of a single recombinant adeno-associated virus derived from serotypes 1 and 2 to achieve more tightly regulated transgene expression from nonhuman primate muscle. Mol Ther 2004; 9: 410-418.
18. Chtarto A, Bender HU, Hanemann CO, Kemp T, Lehtonen E, Levivier M et al. Tetracycline-inducible transgene expression mediated by a single AAV vector. Gene Therapy 2003; 10: 84-94.
19. Sanftner LM, Rivera VM, Suzuki BM, Feng L, Berk L, Zhou S et al. Dimerizer regulation of AADC expression and behavioral response in AAV-transduced 6-OHDA lesioned rats. Mol Ther 2006; 13: 167-174.
20. Lebherz C, Auricchio A, Maguire AM, Rivera VM, Tang W, Grant RL et al. Long-term inducible gene expression in the eye via adeno-associated virus gene transfer in nonhuman primates. Hum Gene Ther 2005; 16: 178-186.
21. Rivera VM, Gao GP, Grant RL, Schnell MA, Zoltick PW, Rozamus LW et al. Long-term pharmacologically regulated expression of erythropoietin in primates following AAV-mediated gene transfer. Blood 2005; 105: 1424-1430.
22. Flotte TR, Zeitlin PL, Reynolds TC, Heald AE, Pedersen P, Beck S et al. Phase I trial of intranasal and endobronchial administration of a recombinant adeno-associated virus serotype 2 (rAAV2)-CFTR vector in adult cystic fibrosis patients: A two-part clinical study. Hum Gene Ther 2003; 14: 1079-1088.
23. Flotte TR, Schwiebert EM, Zeitlin PL, Carter BJ, Guggino WB. Correlation between DNA transfer and cystic fibrosis airway epithelial cell correction after recombinant adeno-associated virus serotype 2 gene therapy. Hum Gene Ther 2005; 16: 921-928.
24. Virella-Lowell I, Zusman B, Foust K, Loiler S, Conlon T, Song S et al. Enhancing rAAV vector expression in the lung. J Gene Med 2005; 7: 842-850.
25. Hildinger M, Auricchio A, Gao G, Wang L, Chirmule N, Wilson JM. Hybrid vectors based on adeno-associated virus serotypes 2 and 5 for muscle-directed gene transfer. J Virol 2001; 75: 6199-6203.
26. Davidoff AM, Gray JT, Ng CY, Zhang Y, Zhou J, Spence Y et al. Comparison of the ability of adeno-associated viral vectors pseudotyped with serotype 2, 5, and 8 capsid proteins to mediate efficient transduction of the liver in murine and nonhuman primate models. Mol Ther 2005; 11: 875-888.
27. Ngoi SM, Chien AC, Lee CG. Exploiting internal ribosome entry sites in gene therapy vector design. Curr Gene Ther 2004; 4: 15-31.
28. Ito H, Goater JJ, Tiyapatanaputi P, Rubery PT, O'Keefe RJ, Schwarz EM. Light-activated gene transduction of recombinant adeno-associated virus in human mesenchymal stem cells. Gene Therapy 2004; 11: 34-41.
29. Ulrich-Vinther M, Stengaard C, Schwarz EM, Goldring MB, Soballe K. Adeno-associated vector mediated gene transfer of transforming growth factor-beta1 to normal and osteoarthritic human chondrocytes stimulates cartilage anabolism. Eur Cell Mater 2005; 10: 40-59.
30. Kapturczak M, Zolotukhin S, Cross J, Pileggi A, Molano RD, Jorgensen M et al. Transduction of human and mouse pancreatic islet cells using a bicistronic recombinant adeno-associated viral vector. Mol Ther 2002; 5: 154-160.
31. Fang J, Qian JJ, Yi S, Harding TC, Tu GH, VanRoey M et al. Stable antibody expression at therapeutic levels using the 2A peptide. Nat Biotechnol 2005; 23: 584-590.
32. Marasco WA. Therapeutic antibody gene transfer. Nat Biotechnol 2005; 23: 551-552.
33. Lipshutz GS, Titre D, Brindle M, Bisconte AR, Contag CH, Gaensler KM. Comparison of gene expression after intraperitoneal delivery of AAV2 or AAV5 in utero. Mol Ther 2003; 8: 90-98.
34. Xu Z, Yue Y, Lai Y, Ye C, Qiu J, Pintel DJ et al. Trans-splicing adeno-associated viral vector-mediated gene therapy is limited by the accumulation of spliced mRNA but not by dual vector coinfection efficiency. Hum Gene Ther 2004; 15: 896-905.
35. Reich SJ, Auricchio A, Hildinger M, Glover E, Maguire AM, Wilson JM et al. Efficient trans-splicing in the retina expands the utility of adeno-associated virus as a vector for gene therapy. Hum Gene Ther 2003; 14: 37-44.
36. Liu X, Luo M, Zhang LN, Yan Z, Zak R, Ding W et al. Spliceosome-mediated RNA trans-splicing with recombinant adeno-associated virus partially restores cystic fibrosis transmembrane conductance regulator function to polarized human cystic fibrosis airway epithelial cells. Hum Gene Ther 2005; 16: 1116-1123.
37. Lai Y, Yue Y, Liu M, Ghosh A, Engelhardt JF, Chamberlain JS et al. Efficient in vivo gene expression by trans-splicing adeno-associated viral vectors. Nat Biotechnol 2005; 23: 1435-1439.
38. Yan Z, Zak R, Zhang Y, Engelhardt JF. Inverted terminal repeat sequences are important for intermolecular recombination and circularization of adeno-associated virus genomes. J Virol 2005; 79: 364-379.
39. Yen L, Svendsen J, Lee JS, Gray JT, Magnier M, Baba T et al. Exogenous control of mammalian gene expression through modulation of RNA self-cleavage. Nature 2004; 431: 471-476.
40. Tomar RS, Matta H, Chaudhary PM. Use of adeno-associated viral vector for delivery of small interfering RNA. Oncogene 2003; 22: 5712-5715.
41. Pinkenburg O, Platz J, Beisswenger C, Vogelmeier C, Bals R. Inhibition of NF-kappaB mediated inflammation by siRNA expressed by recombinant adeno-associated virus. J Virol Methods 2004; 120: 119-122.
42. Zhang W, Singam R, Hellermann G, Kong X, Juan HS, Lockey RF et al. Attenuation of dengue virus infection by adenoassociated virus-mediated siRNA delivery. Genet Vaccines Ther 2004; 2: 8.
43. Babcock AM, Standing D, Bullshields K, Schwartz E, Paden CM, Poulsen DJ. In vivo inhibition of hippocampal Ca2+/calmodul-independent protein kinase II by RNA interference. Mol Ther 2005; 11: 899-905.
44. Xia H, Mao Q, Eliason SL, Harper SQ, Martins IH, Orr HT et al. RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat Med 2004; 10: 816-820.
45. Goyenvalle A, Vulin A, Fougerousse F, Leturcq F, Kaplan JC, Garcia L et al. Rescue of dystrophic muscle through U7 snRNAmediated exon skipping. Science 2004; 306: 1796-1799.
46. Yu JY, Taylor J, DeRuiter SL, Vojtek AB, Turner DL. Simultaneous inhibition of GSK3alpha and GSK3beta using hairpin siRNA expression vectors. Mol Ther 2003; 7: 228-236.
47. McCarty DM, Fu H, Monahan PE, Toulson CE, Naik P, Samulski RJ. Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo. Gene Therapy 2003; 10: 2112-2118.
48. Wang Z, Ma HI, Li J, Sun L, Zhang J, Xiao X. Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo. Gene Therapy 2003; 10: 2105-2111.
49. Ren C, Kumar S, Shaw DR, Ponnazhagan S. Genomic stability of self-complementary adeno-associated virus 2 during early stages of transduction in mouse muscle in vivo. Hum Gene Ther 2005; 16: 1047-1057.
50. Xu D, McCarty D, Fernandes A, Fisher M, Samulski RJ, Juliano RL. Delivery of MDR1 small interfering RNA by self-complementary recombinant adeno-associated virus vector. Mol Ther 2005; 11: 523-530.
51. Nakai H, Wu X, Fuess S, Storm TA, Munroe D, Montini E et al. Large-scale molecular characterization of adeno-associated virus vector integration in mouse liver. J Virol 2005; 79: 3606-3614.
52. Schnepp BC, Clark KR, Klemanski DL, Pacak CA, Johnson PR. Genetic fate of recombinant adeno-associated virus vector genomes in muscle. J Virol 2003; 77: 3495-3504.
53. Miller DG, Petek LM, Russell DW. Adeno-associated virus vectors integrate at chromosome breakage sites. Nat Genet 2004; 36: 767-773.
54. Miller DG, Trobridge GD, Petek LM, Jacobs MA, Kaul R, Russell DW. Large-scale analysis of adeno-associated virus vector integration sites in normal human cells. J Virol 2005; 79: 11434-11442.
55. McCarty DM, Young Jr SM, Samulski RJ. Integration of adeno-associated virus (AAV) and recombinant AAV vectors. Annu Rev Genet 2004; 38: 819-845.
56. Huttner NA, Girod A, Schnittger S, Schoch C, Hallek M, Buning H. Analysis of site-specific transgene integration following cotransduction with recombinant adeno-associated virus and a rep encodingplasmid. J Gene Med 2003; 5: 120-129.
57. Goncalves MA. Adeno-associated virus: From defective virus to effective vector. Virol J 2005; 2: 43.
58. Recchia A, Perani L, Sartori D, Olgiati C, Mavilio F. Site-specific integration of functional transgenes into the human genome by adeno/AAV hybrid vectors. Mol Ther 2004; 10: 660-670.
59. Hendrie PC, Russell DW. Gene targeting with viral vectors. Mol Ther 2005; 12: 9-17.
60. Kohli M, Rago C, Lengauer C, Kinzler KW, Vogelstein B. Facile methods for generating human somatic cell gene knockouts using recombinant adeno-associated viruses. Nucleic Acids Res 2004; 32: E3.
61. Miller DG, Petek LM, Russell DW. Human gene targeting by adeno-associated virus vectors is enhanced by DNA double-strand breaks. Mol Cell Biol 2003; 23: 3550-3557.
62. Chamberlain JR, Schwarze U, Wang PR, Hirata RK, Hankenson KD, Pace JM et al. Gene targeting in stem cells from individuals with osteogenesis imperfecta. Science 2004; 303: 1198-1201.